A new survey of health economics and outcomes research (HEOR) leaders in pharmaceutical companies found a high level of confidence that the industry will continue to invest in such research, says a study from Center for the Evaluation of Value and Risk in Health. Ninety-two percent of respondents said they think HEOR will be used more frequently by their companies in the future. In addition, 55 percent said FDAMA Section 114 has been a useful channel for promotion of health economics information, and 49 percent said the U.S. government should use cost-effectiveness analysis in coverage and reimbursement decisions. More information here. (Source: Expert Reviews, 2013).
Provided through Pharmaceutical Training Int'l. Addresses data requirements, methods, regulatory issues, keys to good study design, and economic modeling methods. Access materials anytime, anywhere using our unique internet portal
The ISPOR Asia Consortium Education Committee Distance Learning & Onsite Training subcommittee is proud to announce three Chinese Distance Learning Modules: “Introduction to Outcomes Research,” “Use of Public Data in Health Outcomes Research,” and “Health-Related Quality of Life (HRQOL)
Confirmatory Factor Analysis e-course from Center for Statistical Information introduces confirmatory factor analysis (CFA) using AMOS. As such, it is a basic and applied introduction into latent variable modeling. The module starts with the theoretical ideas behind this method but quickly delves into applied aspects of conducting CFAs. Most of the module is spent on how to create, run, and interpret CFAs. Participants will be provided with demonstrations and trainings that guide you throug